hydrazine has been researched along with Neoplasms in 216 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 95 (43.98) | 18.7374 |
| 1990's | 27 (12.50) | 18.2507 |
| 2000's | 11 (5.09) | 29.6817 |
| 2010's | 55 (25.46) | 24.3611 |
| 2020's | 28 (12.96) | 2.80 |
| Authors | Studies |
|---|---|
| Ahnert, JR; Albittar, AA; Dalal, S; Dev, R; Fu, S; Hui, D; Karp, DD; Liu, S; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Rubin, L; Tsimberidou, AM; Yap, TA; Zarifa, A; Zhong, LL | 1 |
| Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
| Addison, CL; Brun, EMSP; Calvert, ND; Garipov, R; Kirby, A; Melkus, G; Shuhendler, AJ; Suchý, M | 1 |
| Araújo, TG; da Costa Guerra, JF; de Oliveira Júnior, RJ; de Souza Bontempo, NJ; de Souza, TR; Goulart, LR; Guerra, W; Lima, PMAP; Lino, RC; Machado, PHA; Martins, IC; Morelli, S; Orsolin, PC; Paixão, DA; Sousa, LM; Teixeira, SC; Van Petten de Vasconcelos Azevedo, F | 1 |
| Hanaoka, M; Nishie, K; Sato, S | 1 |
| Das, S; Das, U; Dimmock, JR; Hall, SC; Hossain, M; Roayapalley, PK; Roth, SM; Wiggington, PJ | 1 |
| Chen, CH; Fang, ZY; Lv, PC; Ni, LQ; Sun, J; Wu, YF; Zhang, YH; Zheng, Q | 1 |
| Bhatta, R; Han, J; Li, H; Wang, H; Zhou, J | 1 |
| Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
| Adhikari, N; Banerjee, S; Biswas, S; Ghosh, B; Jha, T; Patel, T; Paul, M; Pulya, S; Routholla, G | 1 |
| Fukasawa, K; Hanada, K; Hayashi, Y; Hinata, H; Hirai, H; Imai, S; Itoh, F; Ohfusa, R; Takayama, K | 1 |
| Ding, Y; Liu, B; Lu, L; Zheng, P; Zhou, C | 1 |
| Adhikari, N; Baidya, SK; Banerjee, S; Ghosh, B; Jha, T | 1 |
| Guo, M; Hou, G; Li, Z; Qian, J; Suo, A; Wang, J; Wang, Y; Xu, W | 1 |
| Gao, J; He, W; Huang, S; Song, M; Wu, X; Zhao, Z | 1 |
| Chen, W; Li, L; Liu, Y; Zeng, X | 1 |
| Penketh, P; Shyam, K; Williamson, H | 1 |
| Faisal, A; Furqan, M; Mithani, A; Saleem, RSZ; Ullah, R; Zahra, R | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Baumann, RP; Penketh, PG; Shyam, K; Williamson, HS | 1 |
| Fonseca, GWPD; von Haehling, S | 1 |
| Hariyanto, TI; Kurniawan, A | 1 |
| Bean, S; Carter, BW; Colen, R; Gong, J; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Ogbonna, DC; Pant, S; Piha-Paul, SA; Shah, J; Subbiah, V; Thein, KZ; Tsimberidou, A; Zarifa, A | 1 |
| Gong, W; Kleist, C; Müller-Tidow, C; Neuber, B; Ni, M; Sauer, T; Schmitt, A; Schmitt, M; Schubert, ML; Sellner, L; Stock, S; Wang, L; Wang, S; Yao, H | 1 |
| Guo, Y; He, N; Li, R; Lu, L; Wang, J; Wu, L; Zhang, L; Zhang, X; Zhen, H; Zhou, M | 1 |
| Basen-Engquist, K; Bruera, E; Dev, R; Fellman, BM; Hui, D; Maddi, R; Reuben, JM; Shete, S; Williams, JL; Yennurajalingam, S | 1 |
| Kisby, GE; Spencer, PS | 1 |
| Asai, A; Fukunishi, S; Goto, M; Higuchi, K; Nishiguchi, S; Nishikawa, H | 1 |
| Chen, P; Dong, Y; Liang, G; Wang, F; Zheng, Z; Zhu, Y | 1 |
| Kurokawa, T; Ohkohchi, N | 1 |
| Currow, DC; Skipworth, RJ | 1 |
| Garcia, JM; Graf, SA | 1 |
| Bauer, S; Burgess, P; Doerfel, S; Forget, F; Kalambakas, S; Karaszewska, B; Khan, D; Mostafa Kamel, Y; Safran, H; Winer, ES | 1 |
| Garcia, JM | 1 |
| Chuai, Y; Dai, G; Nie, W; Wang, A; Zhang, X | 1 |
| Crawford, J | 2 |
| Chen, C; Sun, W; Wang, P; Wang, X; Wang, Y | 1 |
| Childs, DS; Jatoi, A | 1 |
| Burke, RT; Doak, AE; Marcus, JM; Orth, JD; Park, S | 1 |
| Choi, YJ; Hai, PT; Han, SB; Huan, LC; Huong, LT; Kang, JS; Linh, NTP; Nam, NH; Park, EJ; Phuong, CV; Thuan, NT; Tran, PT; Truc, LC | 1 |
| Jin, Y; Qiang, W; Shen, A; Zhang, F | 1 |
| Gaidhane, A; Gaidhane, S; Khatib, MN; Quazi, ZS | 1 |
| Chen, Z; Huang, W; Liu, S; Meng, X; Shi, Y; Song, L; Zhao, M; Zhao, Q; Zou, L | 1 |
| Advani, PG; Advani, SM; Jafri, SH; VonVille, HM | 1 |
| Kasvis, P; Vigano, A; Vigano, M | 1 |
| Malik, JS; Yennurajalingam, S | 1 |
| Cen, X; Jie, H; Li, Y; Li, Z; Lin, Y; Liu, C; Qian, X; Tao, L; Yang, S; Zhang, H; Zhao, Y; Zhou, Y; Zuo, Z | 1 |
| Dong, Y; Gong, P; Hu, H; Li, M; Wang, R; Zhang, X; Zhao, Y | 1 |
| Gibiansky, E; Hayes, S; Johnson, BM; Mudd, PN; Ouellet, D; Williams, D | 1 |
| Kumar, P; Narasimhan, B | 1 |
| Barnard, S; Bear, MD; Bernabe, LF; Borgatti, A; Henson, M; Ito, D; Jensen, K; Kauffman, M; Kisseberth, WC; London, CA; McCauley, D; Modiano, JF; Pennell, ML; Saint-Martin, JR; Shacham, S; Wilson, H | 1 |
| Baumann, RP; Ishiguro, K; Penketh, PG; Sartorelli, AC; Shyam, K; Zhu, R | 1 |
| Chatrou, M; Kusters, D; Reutelingsperger, CP; Schurgers, L; Ungethüm, L | 1 |
| Brissos, RF; Caballero, AB; Carvalho Pires, W; Caubet, A; dos Santos Mello, FM; Gamez, P; Massera, C; Roubeau, O; Silveira-Lacerda, Ede P; Teat, SJ; Torrents, E | 1 |
| Forget, F; Hartner, L; Johnson, BM; Karaszewska, B; Kumar, K; Mayer, B; Messam, CA; Mostafa Kamel, Y; Ramlau, R; Richards, DA; Safran, H; Winer, ES | 1 |
| Allen, S; Boccia, RV; Duus, EM; Friend, J; Garcia, JM; Graham, CD; Yan, Y | 1 |
| Baracos, VE | 1 |
| King, I; Nassar, AF; Wisnewski, A | 1 |
| Kuter, DJ | 1 |
| Cerezuela Fuentes, P; García Coronel, M; García Lagunar, MH; Gutiérrez-Meca Maestre, DP; Martínez Ortiz, MJ; Martínez Penella, M | 1 |
| Criscitiello, C; Curigliano, G; Di Leo, M; Esposito, A; Gelao, L; Liuzzi, R; Locatelli, M; Massaro, M; Milani, A; Minchella, I; Pravettoni, G | 1 |
| Meriggi, F | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Aiello, F; Garofalo, A; Grande, F; Neamati, N | 1 |
| Mahipal, A; Malafa, M | 1 |
| Chen, P; Li, G; Liang, G; Tang, W; Wang, L; Yuan, Y; Zhang, H; Zheng, Z; Zhu, H | 1 |
| Hosseinimehr, SJ; Torabizadeh, SA | 1 |
| Azmi, AS; Mohammad, RM | 1 |
| Bai, Y; Hu, Y; Hua, Z; Xu, J; Yu, X; Zhao, Y; Zhao, Z | 1 |
| Burd, CE; Crochiere, M; Elloul, S; Elnaggar, O; Farren, MR; Hennessey, RC; Kashyap, T; Kendra, K; Klebanov, B; Landesman, Y; Lesinski, GB; Shakya, R; Young, G | 1 |
| Wang, M; Yu, N | 1 |
| Baumann, RP; Penketh, PG; Sartorelli, AC; Seow, HA; Shyam, K | 1 |
| Pigneux, A | 1 |
| Aiello, F; Cao, X; Garofalo, A; Grande, F; Neamati, N; Oshima, T; Plasencia, C; Sanchez, T; Yamada, R | 1 |
| Barak, Y; Contag, CH; Debeer, D; Matin, A; Schreiber, F; Thorne, SH | 1 |
| Bondarenko, IN; Jagiello-Gruszfeld, A; Kellum, A; Messam, C; Mostafa Kamel, Y; Patwardhan, R | 1 |
| Bussel, JB; Pinheiro, MP | 1 |
| Du, J; King, I; Nassar, AE | 1 |
| Bailly, C; Guilbaud, N; Guminski, Y; Imbert, T; Kruczynski, A; Le Pape, A; Lerondel, S; Pesnel, S; Pillon, A | 1 |
| Huo, L; Wang, G; Xu, W; Zhang, D; Zhao, G | 1 |
| Akintujoye, OM; Baumann, RP; Glazer, PM; Ishiguro, K; Liu, Y; Penketh, PG; Rockwell, S; Sartorelli, AC; Seow, HA; Shyam, K | 1 |
| Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM | 1 |
| Ghosh, S; Kumar, D; Maruthi Kumar, N; Shah, K | 1 |
| Barsoum, J; Beaudette-Zlatanova, BC; Blackman, RK; Chimmanamada, D; Chu, J; Inoue, T; Koya, K; Lu, R; Nagai, M; Shin Ogawa, L; Vo, NH; Wada, Y | 1 |
| Hebar, A; Rütgen, BC; Selzer, E | 1 |
| Luo, Z; Nitin, N; Samadzadeh, KM; Tikekar, RV | 1 |
| ROSS, WC; WARWICK, GP | 1 |
| ANDERSON, W; EVANS, HD; MAYNEORD, WV; ROSEN, D | 1 |
| BOLLAG, W; GRUNBERG, E | 1 |
| BERNEIS, K; BOLLAG, W; KAISER, A; KOFLER, M; LANGEMANN, A | 1 |
| AMIEL, JL; BERUMEN, L; BRULE, G; CATTAN, A; MATHE, G; SCHNEIDER, M; SCHWARZENBERG, L; SCHWEISGUTH, O | 1 |
| KRUGLOVA, GV | 1 |
| CHISTOVICH, AN; LISITSIN, MS; POPOV, VI; PROKHODTSEV, II; RESHETOV, AI; RYZHKOV, SV; SITENKO, VM; ZERNOV, AI | 1 |
| CHEKULAEV, G; TARASENKO, A | 1 |
| VILNER, LS | 1 |
| RABKOVA, LM | 1 |
| IAROSHEVSKII, FIu; VOLOKHONSKAIA, ML; VORONKO, ND; VYSHESLAVTSEV, SI | 1 |
| BACKHOUSE, TW; SICHER, K | 1 |
| CHANG, CN; HU, Y; WANG, TT | 1 |
| ISHIGURO, M; KAMETANI, T; MIZUNO, D; OGASAWARA, K; SATOH, Y; SHIBUYA, S; UMEZAWA, O | 1 |
| ISHIGURO, M; KAMETANI, T; MIZUNO, D; UMEZAWA, O; YAGI, H | 1 |
| ISHIGURO, M; KAMETANI, T; MIZUNO, D; OGASAWARA, K; SHIBUYA, S; UMEZAWA, O | 1 |
| BOLLAG, W; D ALESSANDRI, A; KEEL, HJ; MARTZ, G | 1 |
| LANCASTER, MC; ROE, FJ | 1 |
| GROGAN, CH; RICE, LM | 1 |
| ADAMSON, RH; DAVIDSON, JD; DION, RL; LOO, TL | 1 |
| CHENG, CC; FRENCH, FA; NYBERG, WH; PODREBARAC, EG | 1 |
| GARCES, B; SANZ ANTON, J | 1 |
| BIANCIFIORI, C; BUCCIARELLI, E; CLAYSON, DB; SANTILLI, FE | 1 |
| KARNOFSKY, DA | 1 |
| AMIEL, JL; CATTAN, A; MATHE, G; SCHLUMBERGER, JR; SCHNEIDER, M; SCHWARZENBERG, L | 1 |
| FINGER, H; FRETZDORFF, AM; SCHNEIDER, F; SEYNSCHE, K; WEITZEL, G | 1 |
| BAENAHERRERA, L; GONZALEZRODRIGUEZ, D; GOSALVEZGOSALVEZ, M; GUIJOSAPERNUS, J | 1 |
| TODD, ID | 1 |
| NEWTON, KA; WESTBURY, G; WHITE, WF | 1 |
| ABATUCCI, JS; JACOB, P; VIALLANEIX, JP | 1 |
| GIUSEPPE, M; PAOLO, I | 1 |
| BRUNNER, KW; YOUNG, CW | 1 |
| BRULE, G; GRISCELLI, C; SCHLUMBERGER, JR | 1 |
| MARTIN, H; SCHUBERT, C; WOERNER, W | 1 |
| KEIDAN, SE | 2 |
| Chu, E; Clairmont, C; Egorin, M; Kummar, S; Modiano, M; Murren, J; Sznol, M | 1 |
| Penketh, PG; Rockwell, S; Sartorelli, AC; Seow, HA; Shyam, K | 1 |
| Ishiguro, K; Penketh, PG; Sartorelli, AC; Shyam, K | 1 |
| Kennedy, N; Krishnadasan, A; Morgenstern, H; Ritz, B; Zhao, Y | 1 |
| Blot, WJ; Boice, JD; Brill, AB; Cohen, SS; Fryzek, JP; Henderson, BE; Marano, DE; McLaughlin, JK; Mumma, MT | 1 |
| Berkenblit, A; Dahl, TA; Dezube, BJ; Eder, JP; Ryan, DP; Seiden, MV; Sherman, ML; Supko, JG; Tatsuta, N | 1 |
| Tatarinov, YS | 1 |
| Suskind, RR | 1 |
| Bonsall, J; Boreham, J; Doll, R; Wald, N | 1 |
| Block, JB; Chlebowski, RT; Heber, D; Richardson, B | 1 |
| Cameron, IL | 1 |
| Regelson, W | 1 |
| Gold, J | 6 |
| Danova, LA; Filov, VA; Gershanovich, ML; Ivin, BA | 2 |
| Takemura, N | 1 |
| Toth, B | 1 |
| Densem, JW; Doll, R; Morris, J; Wald, NJ | 1 |
| Filov, VA | 1 |
| Bruera, E | 3 |
| Herbert, V | 1 |
| DeGraff, W; Gamson, J; Keefer, LK; Krishna, MC; Mitchell, JB; Wink, DA | 1 |
| Ovesen, LF | 1 |
| Jenks, S | 1 |
| Bruera, E; Vigano, A; Watanabe, S | 1 |
| Wheeler, BM | 1 |
| Veggeberg, S | 1 |
| Kaegi, E | 1 |
| Tannock, IF; Warr, DG | 1 |
| Bozzetti, F | 1 |
| Bégin, M; Kaegi, E | 1 |
| Froines, J; Moncau, J; Morgenstern, H; Ritz, B | 1 |
| Levey, GS; Vesely, DL | 1 |
| Back, KC; Carter, VL; Thomas, AA | 1 |
| Regelson, W; Spremulli, E; Wampler, GL | 1 |
| Baló, J | 1 |
| Conso, F; Efthymiou, ML; Garnier, R; Gaultier, M; Riboulet, G | 1 |
| Danova, LA; Filov, VA; Gershanovich, ML; Kondrat'ev, VB; Seĭts, IF | 1 |
| Friedman, MA; Hawkins, MJ | 1 |
| Gorter, R | 1 |
| Breĭvis, PV; Danova, LA; Dement'eva, NP; Filov, VA; Gershanovich, ML; Ivin, BA; Kas'ianenko, IV; Lisitsa, AM; Mindlin, SS; Ragaĭshene, VP | 1 |
| Burch, PA; Ellison, NM; Goldberg, RM; Loprinzi, CL; Michalak, JC | 1 |
| Smigel, K | 1 |
| Denisov, VL; Savchenkov, MF | 1 |
| Alho, J; Kauppinen, T; Sundquist, E | 1 |
| Chlebowski, RT; Heber, D | 1 |
| Block, JB; Bulcavage, L; Chi, J; Chlebowski, JS; Chlebowski, RT; Grosvenor, M; Heber, D; Oktay, E; Scrooc, M; Tsunokai, R | 1 |
| Wald, NJ | 1 |
| Falkson, G; Falkson, HC | 2 |
| Rastetter, J; Stockhusen, G; Theml, H; Trepel, F | 1 |
| Alexanian, R; Frei, E; Howe, CD; Leary, WV; Samuels, ML | 1 |
| Lesobre, R; Ruffino, J; Tubiana, M | 1 |
| Enomoto, M; Saito, M | 1 |
| Clavel, B | 1 |
| Hawks, A; Hicks, RM; Holsman, JW; Magee, PN | 1 |
| Krueger, GR | 1 |
| Wie, H | 1 |
| Hunter, B; Mawdesley-Thomas, LE; Worden, AN | 1 |
| Shimizu, H; Toth, B | 1 |
| Brunner, KW | 1 |
| Seidenglanz, G | 1 |
| Massenti, S; Polese, E; Rossi-Torelli, M | 1 |
| Hanley, T; Udall, V; Weatherall, M | 1 |
| Chahinian, P; Depierre, A; Israel, L | 1 |
| el-Akkad, SM; Garrett, MJ; Glazebrook, GA; Shakir, MA | 1 |
| Magee, PN | 1 |
| Connors, TA | 1 |
| Bosnar, M; Krieg, R; Ringleb, D; Sauer, D; Steckenmesser, R | 1 |
| Cunningham, T; Horton, J; Hosley, H; Olson, KB; Paladine, WJ; Pratt, KL; Sullivan, J; Treble, DH | 1 |
| Billmeier, GJ; Holton, CP | 1 |
| Furue, H; Hattori, T; Kubo, A; Nakao, I; Yamana, T | 1 |
| Hammer, B | 1 |
| Massenti, S; Perri, G | 1 |
| Agati, G | 1 |
| DeVita, VT; Rall, DP | 1 |
| Bucher, U; Kummer, H | 1 |
| Amiel, JL; Bernard, J; Bessis, M; Dreyfus, B; Najean, Y; Péquignot, H; Seligmann, M | 1 |
| De Smedt, J; Kenis, Y; Tagnon, HJ | 1 |
| Kühböck, J; Mannheimer, E | 1 |
51 review(s) available for hydrazine and Neoplasms
| Article | Year |
|---|---|
Anamorelin for cancer cachexia.
Topics: Anorexia; Cachexia; Humans; Hydrazines; Neoplasms; Oligopeptides | 2022 |
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Topics: Copper; Humans; Hydrazines; Ionophores; Neoplasms; Platinum; Proteasome Inhibitors | 2022 |
Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Topics: Copper; Humans; Hydrazines; Neoplasms; Reactive Oxygen Species | 2023 |
Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.
Topics: Antineoplastic Agents; Benzoates; Hemorrhage; Humans; Hydrazines; Neoplasms; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Humans; Hydrazines; Lung Neoplasms; Neoplasms; Oligopeptides | 2021 |
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.
Topics: Anorexia; Appetite; Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Growth Differentiation Factor 15; Humans; Hydrazines; Mirtazapine; Neoplasms; Oligopeptides; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thalidomide; Toll-Like Receptor 4; Treatment Outcome | 2021 |
Role of Hydrazine-Related Chemicals in Cancer and Neurodegenerative Disease.
Topics: Animals; Carcinogens; DNA Damage; DNA Repair; Gene Expression Regulation; Humans; Hydrazines; Liver; Neoplasms; Neurodegenerative Diseases; Neurons; Neurotoxins | 2021 |
Cancer Cachexia: Its Mechanism and Clinical Significance.
Topics: Anilides; Animals; Cachexia; Dietary Supplements; Disease Management; Humans; Hydrazines; Neoplasms; Oligopeptides | 2021 |
Platelets in liver disease, cancer and regeneration.
Topics: Animals; Benzoates; Blood Platelets; Cell Movement; Clinical Trials as Topic; End Stage Liver Disease; Fibrosis; Hepatic Stellate Cells; Humans; Hydrazines; Killer Cells, Natural; Liver; Liver Diseases; Liver Regeneration; Neoplasm Metastasis; Neoplasms; Pyrazoles; Regeneration; Shear Strength; Thrombocytopenia; Thrombopoietin | 2017 |
The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
Topics: Anorexia; Body Composition; Body Weight; Cachexia; Clinical Trials as Topic; Disease Management; Humans; Hydrazines; Neoplasms; Oligopeptides; Treatment Outcome | 2017 |
Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Topics: Animals; Anorexia; Cachexia; Humans; Hydrazines; Neoplasms; Oligopeptides; Quality of Life; Receptors, Ghrelin | 2017 |
What is next after anamorelin?
Topics: Anorexia; Biomarkers; Cachexia; Drug Approval; Humans; Hydrazines; Neoplasms; Oligopeptides; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Ghrelin; Research Design | 2017 |
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Humans; Hydrazines; Middle Aged; Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2017 |
A hunger for hunger: a review of palliative therapies for cancer-associated anorexia.
Topics: Adrenal Cortex Hormones; Anorexia; Appetite Stimulants; Cachexia; Cannabinoids; Humans; Hydrazines; Neoplasms; Oligopeptides; Palliative Care | 2019 |
The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.
Topics: Acupuncture Therapy; Adult; Anorexia; Cachexia; Dietary Supplements; Evidence-Based Medicine; Humans; Hydrazines; Medicine, Chinese Traditional; Neoplasms; Oligopeptides; Plant Extracts | 2018 |
Ghrelin as a Promising Therapeutic Option for Cancer Cachexia.
Topics: Animals; Appetite; Cachexia; Cell Proliferation; Ghrelin; Humans; Hydrazines; Mitochondria; Neoplasms; Oligopeptides; Receptors, Ghrelin | 2018 |
Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cachexia; Clinical Trials as Topic; Cytokines; Disease Management; Female; Humans; Hydrazines; Neoplasm Staging; Neoplasms; Oligopeptides; Quality of Life; Treatment Outcome | 2018 |
Health-related quality of life across cancer cachexia stages.
Topics: Adrenal Cortex Hormones; Anorexia; Appetite Stimulants; Cachexia; Cannabinoids; Cyproheptadine; Female; Health Status; Humans; Hydrazines; Male; Megestrol Acetate; Middle Aged; Neoplasms; Oligopeptides; Quality of Life; Serotonin Antagonists; Severity of Illness Index; Stress, Psychological; Surveys and Questionnaires | 2019 |
Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Topics: Cachexia; Forecasting; Gastrointestinal Agents; Ghrelin; Humans; Hydrazines; Metoclopramide; Neoplasms; Oligopeptides | 2019 |
Hydrazides/hydrazones as antimicrobial and anticancer agents in the new millennium.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Bacteria; Cell Proliferation; Fungi; Humans; Hydrazines; Hydrazones; Neoplasms | 2013 |
Managing thrombocytopenia associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Benzoates; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Gemcitabine; Humans; Hydrazines; Neoplasms; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2015 |
Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Topics: Animals; Anorexia; Cachexia; Humans; Hydrazines; Neoplasms; Oligopeptides; Receptors, Ghrelin; Syndrome | 2015 |
Cancer Cachexia: One Step Ahead.
Topics: Cachexia; Combined Modality Therapy; Disease Progression; Female; Humans; Hydrazines; Male; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Nutritional Support; Oligopeptides; Physical Therapy Modalities; Prognosis; Severity of Illness Index; Treatment Outcome | 2015 |
Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Discovery; Humans; Hydrazines; Molecular Structure; Neoplasms; Quinoxalines | 2016 |
Clinical results in cachexia therapeutics.
Topics: Amides; Anilides; Antineoplastic Agents; Cachexia; Combined Modality Therapy; Diet, Healthy; Drugs, Investigational; Exercise; Humans; Hydrazines; Ligands; Muscle, Skeletal; Neoplasms; Oligopeptides; Receptors, Androgen; Receptors, Ghrelin; Wasting Syndrome | 2016 |
Importins and exportins as therapeutic targets in cancer.
Topics: Active Transport, Cell Nucleus; Animals; Cell Nucleus; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Neoplasms; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triazoles | 2016 |
The Influence of Co-Ligands on Improving Tumor Targeting of
Topics: Animals; Chelating Agents; Humans; Hydrazines; Ligands; Neoplasms; Nicotinic Acids; Organotechnetium Compounds; Peptides; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2017 |
Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Topics: Anorexia; Cachexia; Female; Humans; Hydrazines; Neoplasms; Oligopeptides; Quality of Life; Syndrome | 2017 |
Anticancer drug discovery targeting DNA hypermethylation.
Topics: 4-Aminobenzoic Acid; Adenosine; Animals; Antineoplastic Agents; Cytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Design; Enzyme Inhibitors; Humans; Hydrazines; Neoplasms; Oligonucleotides, Antisense; para-Aminobenzoates | 2008 |
Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Humans; Hydrazines; Isocyanates; Middle Aged; Neoplasms; Prodrugs; Sulfonamides | 2009 |
Eltrombopag.
Topics: Animals; Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Mice; Neoplasms; Pyrazoles; Thrombocytopenia | 2011 |
NATURAL, METALLIC AND OTHER SUBSTANCES, AS CARCINOGENS.
Topics: Aluminum; Arsenic; Aspergillus; Beryllium; Carcinogens; Carrageenan; Citrus; Croton Oil; Food Contamination; Fruit; Griseofulvin; Herbicides; Humans; Hydrazines; Insecticides; Iron; Metals; Neoplasms; Neoplasms, Experimental; Penicillium; Plants, Edible; Polysaccharides; Rats; Research; Senecio; Tannins; Thiourea | 1964 |
[Segidrin: a new-type antineoplastic agent].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Gluconeogenesis; Humans; Hydrazines; Mice; Neoplasms; Neoplasms, Experimental; Rats; Time Factors | 1994 |
Is the pharmacological treatment of cancer cachexia possible?
Topics: Adrenal Cortex Hormones; Anorexia; Antineoplastic Agents; Cachexia; Cannabinoids; Clinical Protocols; Cyproheptadine; Enteral Nutrition; Humans; Hydrazines; Neoplasms; Nutritional Status; Parenteral Nutrition; Progestins; Quality of Life | 1993 |
Anorexia and cachexia in advanced cancer patients.
Topics: Adrenal Cortex Hormones; Animals; Anorexia; Antineoplastic Agents; Cachexia; Cannabinoids; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cyproheptadine; Enteral Nutrition; Gastrointestinal Agents; Humans; Hydrazines; Mice; Neoplasms; Nutritional Physiological Phenomena; Parenteral Nutrition; Progestins; Prospective Studies; Randomized Controlled Trials as Topic; Research; Terminal Care | 1994 |
Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.
Topics: Antineoplastic Agents; Cachexia; Drugs, Investigational; Gluconeogenesis; Humans; Hydrazines; Neoplasms; Phosphoenolpyruvate Carboxykinase (GTP) | 1998 |
Hydrazine.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Humans; Hydrazines; Mutagenicity Tests; Mutagens; Neoplasms; Neoplasms, Experimental | 1999 |
Occupational hazards of missile operations with special regard to the hydrazine propellants.
Topics: Alopecia; Animals; Behavior, Animal; Body Weight; Carcinogens; Dimethylhydrazines; Dose-Response Relationship, Drug; Environmental Exposure; Female; Hemolysis; Humans; Hydrazines; Liver; Male; Maximum Allowable Concentration; Metabolism; Monomethylhydrazine; Mutation; Neoplasms; Occupational Diseases; Respiratory Tract Diseases; Seizures; Water Pollution, Chemical | 1978 |
Clinical management of anorexia and cachexia in patients with advanced cancer.
Topics: Anorexia; Cachexia; Cannabinoids; Cyproheptadine; Humans; Hydrazines; Megestrol; Megestrol Acetate; Methylprednisolone; Neoplasms | 1992 |
Current pharmacological management of anorexia in cancer patients.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Cachexia; Cannabinoids; Cyproheptadine; Humans; Hydrazines; Neoplasms | 1992 |
Management of anorexia-cachexia associated with cancer and HIV infection.
Topics: Anorexia; Antineoplastic Agents; Cachexia; Dronabinol; HIV Infections; Humans; Hydrazines; Megestrol; Megestrol Acetate; Metoclopramide; Neoplasms; Palliative Care | 1991 |
Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.
Topics: Anorexia; Cachexia; Cyproheptadine; Dexamethasone; Double-Blind Method; Humans; Hydrazines; Neoplasms; Weight Gain | 1990 |
[Hydrazine derivatives--potentially hazardous carcinogenic chemical compounds].
Topics: Animals; Carcinogens; Dose-Response Relationship, Drug; Humans; Hydrazines; Neoplasms; Neoplasms, Experimental; Occupational Diseases; Structure-Activity Relationship | 1988 |
Hydrazine sulfate: a current perspective.
Topics: Cachexia; Clinical Trials as Topic; Double-Blind Method; Gluconeogenesis; Humans; Hydrazines; Neoplasms; Parenteral Nutrition, Total | 1987 |
Metabolic abnormalities in cancer patients: carbohydrate metabolism.
Topics: Animals; Blood Glucose; Cachexia; Humans; Hydrazines; Neoplasms | 1986 |
[Naturally occurring chemical carcinogens].
Topics: Aflatoxins; Alkaloids; Animals; Anthraquinones; Anti-Bacterial Agents; Carcinogens; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Glycosides; Humans; Hydrazines; Lactones; Liver Neoplasms; Mycotoxins; Neoplasms; Oils; Peptides; Plants, Edible; Pyrrolidines; Tannins | 1970 |
Morphology of chemical immunosuppression.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antibody Formation; Antigen-Antibody Reactions; Antineoplastic Agents; Autoimmune Diseases; Binding Sites, Antibody; Enzymes; Hormones; Humans; Hydrazines; Immune System Diseases; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Mitosis; Molecular Biology; Mycophenolic Acid; Neoplasms; Nitrosourea Compounds; Poly I-C; Pyrans; Transplantation, Homologous | 1972 |
[Progress in the drug therapy of cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cytarabine; Daunorubicin; Drug Synergism; Humans; Hydrazines; Hydroxyurea; Neoplasms; Nitroso Compounds; Picolinic Acids; Pyrogallol; Quinolines; Streptonigrin; Urea | 1968 |
[Chemotherapy of malignant tumors. 44].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Androgens; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Azirines; Carbamates; Colchicine; Dichlorodiphenyldichloroethane; Esters; Estrogens; Ethers, Cyclic; Ethylamines; Excitatory Amino Acid Antagonists; Folic Acid Antagonists; Heterocyclic Compounds; Hormones; Hydrazines; Mannitol; Neoplasms; Phytotherapy; Pipobroman; Plants, Medicinal; Plants, Toxic; Podophyllum; Purines; Pyrimidines; Sulfonic Acids; Triazines; Vinblastine; Vincristine | 1970 |
An industrial view of current practice in predicting drug toxicity.
Topics: Abnormalities, Drug-Induced; Animals; Cataract; Clinical Trials as Topic; Drug Industry; Fertility; Humans; Hydrazines; Neoplasms; Poisoning; Poliovirus Vaccine, Oral; Thiocarbamates; Toxicology; United States; United States Food and Drug Administration | 1970 |
29 trial(s) available for hydrazine and Neoplasms
| Article | Year |
|---|---|
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Topics: Adult; Aged; Anorexia; Antiemetics; Female; Humans; Hydrazines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Triazoles; Vomiting; Young Adult | 2022 |
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptors, Cytoplasmic and Nuclear; Topotecan; Triazoles | 2021 |
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deoxycytidine; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Pyrazoles; Thrombocytosis | 2017 |
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
Topics: Acrylamides; Active Transport, Cell Nucleus; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Nucleus; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Hydrazines; Inhibitory Concentration 50; Male; Neoplasms; Quality of Life | 2014 |
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasm Staging; Neoplasms; Platelet Count; Pyrazoles; Treatment Outcome | 2015 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Paclitaxel; Placebos; Platelet Count; Polypharmacy; Pyrazoles; Treatment Outcome; Young Adult | 2010 |
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hydrazines; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Sulfonamides; Thrombocytopenia | 2005 |
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Paclitaxel; Time Factors; Treatment Outcome | 2007 |
Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss.
Topics: Adult; Aged; Body Weight; Cachexia; Carbohydrate Metabolism; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hydrazines; Male; Middle Aged; Neoplasms | 1984 |
The 'grand conspiracy' against the cancer cure.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Hydrazines; Intestinal Neoplasms; Neoplasms; Skin Neoplasms | 1980 |
Isoniazid--an attempt at retrospective prediction. A report of an ad hoc expert groups of the International Commission for Protection Against Environmental Mutagens and Carcinogens.
Topics: Acetyltransferases; Biotransformation; Carcinogens; Chromosomes; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hydrazines; Inactivation, Metabolic; Isoniazid; Liver; Lung Neoplasms; Mutagens; Neoplasms; Risk; Teratogens; Tuberculosis, Pulmonary | 1980 |
Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate.
Topics: Appetite; Body Weight; Clinical Trials as Topic; Female; Humans; Hydrazines; Neoplasms; Nutritional Physiological Phenomena | 1981 |
Results of clinical study antitumor action of hydrazine sulfate.
Topics: Abdominal Neoplasms; Aged; Clinical Trials as Topic; Female; Humans; Hydrazines; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neuroblastoma; Sarcoma | 1981 |
Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Fibromatosis, Aggressive; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Male; Middle Aged; Neoplasms; Neuroblastoma | 1995 |
Clinical study of hydrazine sulfate in advanced cancer patients.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms | 1979 |
[Experimental and clinical data on the antitumor action of hydrazine sulfate].
Topics: Adult; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Carcinoma, Squamous Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Hodgkin Disease; Humans; Hydrazines; Lethal Dose 50; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Rats; Sarcoma 37; Skin Neoplasms; Sulfates; Time Factors | 1975 |
Clinical management of anorexia and cachexia in patients with advanced cancer.
Topics: Anorexia; Cachexia; Cannabinoids; Cyproheptadine; Humans; Hydrazines; Megestrol; Megestrol Acetate; Methylprednisolone; Neoplasms | 1992 |
[The results of a clinical study of the preparation hydrazine sulfate].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Hydrazines; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Remission Induction; Tablets, Enteric-Coated; Time Factors | 1990 |
Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.
Topics: Anorexia; Cachexia; Cyproheptadine; Dexamethasone; Double-Blind Method; Humans; Hydrazines; Neoplasms; Weight Gain | 1990 |
Hydrazine sulfate used in cancer patients.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Glucose; Humans; Hydrazines; Neoplasms | 1990 |
Hydrazine sulfate: a current perspective.
Topics: Cachexia; Clinical Trials as Topic; Double-Blind Method; Gluconeogenesis; Humans; Hydrazines; Neoplasms; Parenteral Nutrition, Total | 1987 |
Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.
Topics: Appetite; Body Weight; Cachexia; Drug Tolerance; Energy Intake; Humans; Hydrazines; Neoplasms | 1987 |
Clinical trials with N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia.
Topics: Adenocarcinoma; Adult; Aged; Amines; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multiple Myeloma; Mycosis Fungoides; Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor | 1967 |
[Isoniazid and carcinogenesis].
Topics: Adenoma; Adult; Animals; Carbamates; Carcinoma; Child; Clinical Trials as Topic; Female; Humans; Hydrazines; Isoniazid; Lung Neoplasms; Male; Mice; Neoplasms; Neoplasms, Experimental; Pregnancy; Tuberculosis | 1969 |
An industrial view of current practice in predicting drug toxicity.
Topics: Abnormalities, Drug-Induced; Animals; Cataract; Clinical Trials as Topic; Drug Industry; Fertility; Humans; Hydrazines; Neoplasms; Poisoning; Poliovirus Vaccine, Oral; Thiocarbamates; Toxicology; United States; United States Food and Drug Administration | 1970 |
Combination chemotherapy for 418 cases of advanced cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; History, 16th Century; Humans; Hydrazines; Injections, Intravenous; Laryngeal Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Neoplasms; Prognosis; Time Factors; Tongue Neoplasms; Vinblastine | 1971 |
141 other study(ies) available for hydrazine and Neoplasms
| Article | Year |
|---|---|
Mapping vitamin B
Topics: Cell Line, Tumor; Contrast Media; Humans; Hydrazines; Magnetic Resonance Imaging; Neoplasms; Niacin; Vitamin B 6 | 2021 |
A selective Cu
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Copper; DNA Cleavage; Drug Discovery; Humans; Hydrazines; Mice; Neoplasms; Phenanthrolines | 2021 |
Cytotoxic benzylidene hydrazides of terephthalic acid and related compounds.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Humans; Hydrazines; Neoplasms; Phthalic Acids | 2022 |
Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors.
Topics: Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Hydrazines; Molecular Docking Simulation; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolinones; Structure-Activity Relationship | 2022 |
Recyclable cell-surface chemical tags for repetitive cancer targeting.
Topics: Cell Membrane; Click Chemistry; Fluoresceins; Humans; Hydrazines; Ketones; Neoplasms; Polysaccharides; Sugars; Sulfonic Acids | 2022 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydrazines; Mice; Neoplasms | 2022 |
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Topics: Animals; Biological Products; Cachexia; Disease Models, Animal; Hydrazines; Mice; Muscle, Skeletal; Muscular Atrophy; Myostatin; Neoplasms; Oligopeptides; Peptides; Receptors, Ghrelin; Transforming Growth Factors | 2022 |
Hydrazides as Potential HDAC Inhibitors: Structure-activity Relationships and Biological Implications.
Topics: Histone Deacetylase Inhibitors; Humans; Hydrazines; Neoplasms; Neurodegenerative Diseases; Structure-Activity Relationship | 2023 |
Hydrazide/Metal/Indocyanine Green Coordinated Nanoplatform for Potentiating Reciprocal Ferroptosis and Immunity against Melanoma.
Topics: Cell Line, Tumor; Ferroptosis; Humans; Hydrazines; Indocyanine Green; Infrared Rays; Interferon-gamma; Melanoma; Neoplasms; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2023 |
Physicochemical Considerations of Tumor Selective Drug Delivery and Activity Confinement with Particular Reference to 1,2-Bis(Sulfonyl)-1- Alkylhydrazines Delivery.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Hydrazines; Hypoxia; Neoplasms; Prodrugs | 2020 |
A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brefeldin A; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Humans; Hydrazines; Hydrazones; Neoplasms; Quinolines; Quinuclidines; Sulfonamides; Tyrphostins | 2020 |
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazines.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Hydrazines; Neoplasms; Prodrugs | 2021 |
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
Topics: Active Transport, Cell Nucleus; Antigens, CD19; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Combined Modality Therapy; Cytoplasm; Exportin 1 Protein; Humans; Hydrazines; Immunotherapy, Adoptive; Karyopherins; Neoplasms; Receptors, Chimeric Antigen; Receptors, Cytoplasmic and Nuclear; STAT3 Transcription Factor; Time Factors; Triazoles | 2021 |
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Topics: A549 Cells; Antineoplastic Agents; Histone Demethylases; Humans; Hydrazines; Janus Kinases; Neoplasm Proteins; Neoplasms; Signal Transduction; STAT3 Transcription Factor; Sulfonamides | 2021 |
Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study.
Topics: Counseling; Exercise; Fatigue; Humans; Hydrazines; Longitudinal Studies; Neoplasms; Oligopeptides; Prospective Studies | 2022 |
Bioluminescent Turn-On Probe for Sensing Hypochlorite in Vitro and in Tumors.
Topics: Firefly Luciferin; Hydrazines; Hypochlorous Acid; Limit of Detection; Luminescent Agents; Luminescent Measurements; Molecular Imaging; Neoplasms; Oxidants | 2017 |
Cancer cachexia: Are we ready to take a step forward?
Topics: Cachexia; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Ghrelin; Humans; Hydrazines; Lung Neoplasms; Neoplasms; Oligopeptides | 2018 |
pH-responsive nanoreservoirs based on hyaluronic acid end-capped mesoporous silica nanoparticles for targeted drug delivery.
Topics: Drug Delivery Systems; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrazines; Hydrogen-Ion Concentration; Nanoparticles; Neoplasms; Silicon Dioxide | 2018 |
Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Lineage; Cell Survival; Exportin 1 Protein; G1 Phase; Humans; Hydrazines; Imidazoles; Karyopherins; Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Suppressor Protein p53 | 2018 |
N'-[(E)-Arylidene]-2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-acetohydrazides: Synthesis and Evaluation of Caspase Activation Activity and Cytotoxicity.
Topics: Antineoplastic Agents; Benzoxazines; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Activators; Humans; Hydrazines; Neoplasms; Structure-Activity Relationship | 2018 |
Extending Hypochlorite Sensing from Cells to Elesclomol-Treated Tumors in Vivo by Using a Near-Infrared Dual-Phosphorescent Nanoprobe.
Topics: Animals; Cell Line, Tumor; Cell Survival; HeLa Cells; Humans; Hydrazines; Hypochlorous Acid; Infrared Rays; Iridium; Luminescence; Mice; Nanoparticles; Neoplasms | 2018 |
ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; HCT116 Cells; HeLa Cells; Histone Demethylases; Humans; Hydrazines; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Morpholines; Neoplasms; S Phase; Signal Transduction; Sulfones; Thiazoles; TOR Serine-Threonine Kinases; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrazines; Molecular Structure; Neoplasms; Pyrimidines; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Neoplasms; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome; Young Adult | 2013 |
Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA; Hydrazines; Intercalating Agents; Mice; Neoplasms; Phosphates; Prodrugs; Sulfonamides | 2014 |
Molecular imaging of cell death in tumors. Increasing annexin A5 size reduces contribution of phosphatidylserine-targeting function to tumor uptake.
Topics: Animals; Annexin A5; Apoptosis; Biotin; Half-Life; HT29 Cells; Humans; Hydrazines; Magnetic Resonance Imaging; Mice; Mice, Nude; Microscopy, Confocal; Neoplasms; Phosphatidylserines; Protein Binding; Protein Structure, Tertiary; Radiography; Recombinant Proteins; Streptavidin; Tissue Distribution; Transplantation, Heterologous | 2014 |
Highly cytotoxic DNA-interacting copper(II) coordination compounds.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coordination Complexes; Copper; Crystallography, X-Ray; Cytotoxins; DNA; Humans; Hydrazines; Models, Molecular; Neoplasms | 2014 |
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anabolic Agents; Analysis of Variance; Appetite Stimulants; Body Composition; Cachexia; Clinical Trials, Phase II as Topic; Female; Humans; Hydrazines; Least-Squares Analysis; Male; Middle Aged; Muscle Strength; Neoplasms; Oligopeptides; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; United States; Weight Gain; Young Adult | 2015 |
Skeletal muscle anabolism in patients with advanced cancer.
Topics: Anabolic Agents; Appetite Stimulants; Cachexia; Female; Humans; Hydrazines; Male; Neoplasms; Oligopeptides | 2015 |
Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.
Topics: Animals; Antineoplastic Agents; Humans; Hydrazines; Injections, Intravenous; Male; Metalloporphyrins; Models, Animal; Neoplasms; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Sulfonamides; Tissue Distribution | 2015 |
[Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors].
Topics: Aged; Antineoplastic Agents; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Off-Label Use; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2015 |
Hydrazide d-luciferin for in vitro selective detection and intratumoral imaging of Cu(2.).
Topics: Animals; Benzothiazoles; Cations, Divalent; Cell Line, Tumor; Copper; Humans; Hydrazines; Luciferases, Firefly; Luminescent Agents; Luminescent Measurements; Mice; Neoplasms; Optical Imaging | 2016 |
Targeting Cancer at the Nuclear Pore.
Topics: Animals; Antineoplastic Agents; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Neoplasms; Nuclear Pore; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; CTLA-4 Antigen; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Exportin 1 Protein; Humans; Hydrazines; Immunomodulation; Karyopherins; Melanoma, Experimental; Mice; Neoplasms; Receptors, Cytoplasmic and Nuclear; T-Lymphocytes; Triazoles | 2017 |
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells.
Topics: Animals; Antineoplastic Agents; Catalase; Cell Hypoxia; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Cricetulus; Glucose; Glucose Oxidase; Humans; Hydrazines; Mice; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2008 |
Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Discovery; Female; Flow Cytometry; HT29 Cells; Humans; Hydrazines; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Neoplasms; Quinoxalines; Xenograft Model Antitumor Assays | 2009 |
Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing.
Topics: Animals; Biological Therapy; Biosensing Techniques; Cell Death; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Bacterial; Humans; Hydrazines; Mice; Mice, Inbred BALB C; Neoplasms; Nitric Oxide; Nitric Oxide Donors; Salmonella typhimurium; Time Factors; Tumor Burden | 2010 |
Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).
Topics: Acetylcysteine; Antineoplastic Agents; Carbon Isotopes; Chromatography, High Pressure Liquid; Cysteine; Glutathione; Humans; Hydrazines; Magnetic Resonance Spectroscopy; Microsomes, Liver; NADP; Neoplasms; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2011 |
99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.
Topics: Animals; Biological Transport; Carrier Proteins; Cell Line, Tumor; Drug Stability; Female; Humans; Hydrazines; Luminescent Measurements; Male; Mice; Molecular Imaging; Neoplasms; Niacinamide; Organotechnetium Compounds; Radiochemistry; Spermine; Tomography, Emission-Computed, Single-Photon | 2011 |
Synthesis and cytotoxic activity of novel 3-(1H-indol-3-yl)-1H-pyrazole-5-carbohydrazide derivatives.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; Hydrazines; Models, Molecular; Neoplasms; Pyrazoles; Structure-Activity Relationship | 2011 |
Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cricetinae; DNA Repair; Humans; Hydrazines; Mammary Neoplasms, Animal; Mice; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Radiation Tolerance; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays | 2011 |
Novel bis(indolyl)hydrazide-hydrazones as potent cytotoxic agents.
Topics: Acetic Acid; Animals; Antineoplastic Agents; Catalysis; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrazines; Hydrazones; Indoles; Inhibitory Concentration 50; Models, Chemical; Neoplasms; Porifera | 2012 |
The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Copper; Humans; Hydrazines; Mitochondria; Neoplasms; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species | 2012 |
NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Shape; Cell Size; DNA Damage; DNA Replication; Drug Screening Assays, Antitumor; Humans; Hydrazines; Inhibitory Concentration 50; Neoplasms; Phosphorylation; Quinoxalines; S Phase Cell Cycle Checkpoints; Tumor Suppressor Protein p53 | 2012 |
Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy.
Topics: 4-Chloro-7-nitrobenzofurazan; Analysis of Variance; Antineoplastic Agents; Apoptosis; Cell Survival; Choline; Cisplatin; Deoxyglucose; Fluorescent Dyes; HeLa Cells; Humans; Hydrazines; Microscopy, Fluorescence; Molecular Imaging; Neoplasms; Spheroids, Cellular | 2012 |
Reduction of cytotoxic azo compounds by hydrazine and by the xanthine oxidase-xanthine system.
Topics: Azo Compounds; Benzene; Benzene Derivatives; Hydrazines; Neoplasms; Neoplasms, Experimental; Oxidation-Reduction; Oxidoreductases; Xanthine Oxidase; Xanthines | 1955 |
Hydrogen peroxide yields in x-irradiated aqueous solutions; a sensitive method based on hydrazide chemiluminescence.
Topics: Hydrazines; Hydrogen Peroxide; Luminescence; Neoplasms; X-Rays | 1955 |
Tumour inhibitory effects of a new class of cytotoxic agents: methylhydrazine derivatives.
Topics: Antineoplastic Agents; Cytotoxins; Humans; Hydrazines; Monomethylhydrazine; Neoplasms | 1963 |
The degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxide.
Topics: Antineoplastic Agents; DNA; Hydrazines; Hydrogen Peroxide; Neoplasms | 1963 |
METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HAEMATOSARCOMA AND LEUKAEMIA.
Topics: Antineoplastic Agents; Hodgkin Disease; Hydrazines; Leukemia; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma; Vinblastine | 1963 |
[RESULTS OF THE CLINICAL TRIAL OF TREATING CANCER PATIENTS WITH CADMIUM IODIDE AND SEMICARBAZIDE HC1].
Topics: Cadmium; Cadmium Compounds; Humans; Hydrazines; Iodides; Neoplasms; Semicarbazides | 1963 |
[RESULTS IN THE TREATMENT OF CANCER PATIENTS WITH SEMICARBAZIDE AND CADMIUM].
Topics: Cadmium; Hydrazines; Iodides; Neoplasms; Semicarbazides | 1963 |
[RESULTS OF THE TREATMENT OF PATIENTS WITH NEGLECTED CANCER IN THE LENINGRAD DISTRICT MILITARY HOSPITAL WITH PREPARATIONS PROPOSED BY THE BIOCHEMIST, A. T. KACHUGIN].
Topics: Cadmium; Hospitals, Military; Hydrazines; Iodides; Neoplasms; United States | 1963 |
[DATA ON THE RESULTS OF TREATMENT, AT THE UNITED HOSPITAL OF THE MOSCOW DISTRICT OF LENINGRAD, OF CANCER PATIENTS WITH CADMIUM IODIDE AND SEMICARBAZIDE HC1].
Topics: Cadmium; Cadmium Compounds; Humans; Hydrazines; Iodides; Moscow; Neoplasms; Semicarbazides | 1963 |
[ON THE USE OF CADMIUM IODIDE AND SEMICARBAZIDE HC1 IN THE TREATMENT OF BLADDER CANCERS].
Topics: Cadmium; Cadmium Compounds; Humans; Hydrazines; Iodides; Neoplasms; Semicarbazides; Urinary Bladder Neoplasms | 1963 |
[RESULTS OF THE USE OF SEMICARBAZIDE-CADMIUM THERAPY IN PATIENTS WITH INCURABLE MALIGNANT NEOPLASMS].
Topics: Aged; Cadmium; Humans; Hydrazines; Iodides; Neoplasms; Radioisotopes; Semicarbazides | 1963 |
METHYL-HYDRAZINE IN MALIGNANT DISEASE.
Topics: Antineoplastic Agents; Humans; Hydrazines; Neoplasms | 1963 |
[STUDIES ON CANCER CHEMOTHERAPY. XIX. SYNTHESIS OF N,N-BIS-(BETA-CHLOROETHYL)-HYDRAZONE DERIVATIVES].
Topics: Aldehydes; Androgens; Antineoplastic Agents; Chemistry, Pharmaceutical; Hydrazines; Hydrazones; Methyltestosterone; Neoplasms; Research; Testosterone | 1963 |
[SYNTHESIS OF 2-HALOGENO-4,5-DIALKOXYPHENYLFATTY ACID HYDRAZIDE AND ITS RELATED COMPOUNDS AND THEIR ANTI-CANCER ACTIVITY. (STUDIES ON ANTI-CANCER AGENTS. VII.)].
Topics: Antineoplastic Agents; Benzoates; Chemistry, Pharmaceutical; Cinnamates; Hydrazines; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Pharmacy; Phenylacetates; Research | 1963 |
[THE REACTION OF (2-BROMO-4,5-DIMETHOXYPHENYL)-ACETIC ACID HYDRAZIDE WITH VARIOUS CARBONYL COMPOUNDS AND THEIR ANTI-CANCER ACTIVITY. (STUDIES ON ANTI-CANCER AGENTS. VIII.)].
Topics: Acetic Acid; Antineoplastic Agents; Chemistry, Pharmaceutical; Hydrazines; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Phenylacetates; Research | 1963 |
[SYNTHESIS OF 2-NITRO-4,5-DIMETHOXYPHENYLFATTY ACID HYDRAZIDE AND ITS RELATED COMPOUNDS AND THEIR ANTI-CANCER ACTIVITY. (STUDIES ON ANTI-CANCER AGENTS. X.)].
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Hydrazines; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Phenylacetates; Research | 1963 |
PRELIMINARY CLINICAL RESULTS WITH A NEW ANTITUMOR AGENT RO 4-6467 (NSC-77213).
Topics: Antineoplastic Agents; Bone Marrow Diseases; Eosinophilia; Geriatrics; Hemolysis; Hodgkin Disease; Hydrazines; Leukemia; Leukemia, Lymphoid; Lymphocytosis; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nausea; Neoplasms; Radiography, Thoracic; Toxicology; Vomiting | 1963 |
BICYCLIC IMIDES AND ISOINDOLINES.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Chemistry, Pharmaceutical; Hydrazines; Imides; Indoles; Neoplasms; Neoplasms, Experimental; Pharmacology; Research; Sarcoma 180; Tissue Culture Techniques | 1963 |
HYDROXYMETHYLGLYOXAL BISGUANYLHYDRAZONE.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Hydrazines; Leukemia; Leukemia L1210; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Research; Spectrum Analysis | 1963 |
STUDIES ON METHYLGLYOXAL BIS(GUANYLHYDRAZONE) ANALOGS. I. HOMOLOGS OF METHYLGLYOXAL BIS(GUANYLHYDRAZONE).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Guanidines; Hydrazines; Leukemia L1210; Leukemia, Experimental; Mitoguazone; Neoplasms; Neoplasms, Experimental; Pharmacology; Pyruvaldehyde; Research; Sarcoma 180 | 1963 |
[THE PHARMACOLOGICAL EFFECTS OF THE CYTOSTATIC RO 4-6467 (CLINICAL ASPECTS, HEMATOLOGY AND CYTOLOGY)].
Topics: Antineoplastic Agents; Biomedical Research; Cytostatic Agents; Hematology; Hydrazines; Neoplasms; Pathology; Pharmacology | 1964 |
INDUCTION OF HEPATOMAS IN CBA-CB-SE MICE BY HYDRAZINE SULPHATE AND THE LACK OF EFFECT OF CROTON OIL ON TUMOUR INDUCTION IN BALB-C-CB-SE MICE.
Topics: Animals; Carcinoma, Hepatocellular; Croton Oil; Hydrazines; Isoniazid; Isonicotinic Acids; Liver; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neoplasms; Neoplasms, Experimental; Pathology; Pharmacology; Research; Skin Neoplasms; Sulfates; Toxicology | 1964 |
CURRENT CONCEPTS IN CANCER. 2. HODGKIN'S DISEASE. CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydrazines; Lymphatic Metastasis; Neoplasms; Prognosis; Vinblastine | 1965 |
[ATTEMPT AT TREATMENT OF HODGKIN'S DISEASE AND VARIOUS HEMATOSARCOMAS WITH 1-METHYL-2-P-ALLOPHANOYL-BENZYLHYDRAZINE HYDROBROMIDE].
Topics: Antineoplastic Agents; Hodgkin Disease; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Mycosis Fungoides; Neoplasms; Sarcoma | 1964 |
[STUDIES ON THE CYTOSTATIC MECHANISM OF ACTION OF METHYLHYDRAZINE].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cytostatic Agents; Hydrazines; Methylhydrazines; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Research | 1964 |
[THE TREATMENT OF NEOPLASTIC PROCESSES WITH A NEW PRODUCT DERIVED FROM METHYL-HYDRAZINE (RO 4-6467)].
Topics: Amino Acids; Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydrazines; Neoplasms; Neoplastic Processes | 1964 |
NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Melanoma; Mycosis Fungoides; Neoplasms; Palliative Care; Procarbazine; Toxicology | 1965 |
INTRA-ARTERIAL ADMINISTRATION OF 2-ETHYLHYDRAZIDE OF PODOPHYLLIC ACID (NSC-72274) IN LOCALIZED MALIGNANT DISEASE.
Topics: Antineoplastic Agents; Biomedical Research; Drug Therapy; Hydrazines; Injections, Intra-Arterial; Neoplasms; Podophyllotoxin; Podophyllum; Toxicology | 1964 |
[CLINICAL TRIALS OF A METHYLHYDRAZINE DERIVATIVE AND ITS COMBINATION WITH TELECOBALT THERAPY].
Topics: Antineoplastic Agents; Cobalt Isotopes; Drug Therapy; Esophageal Neoplasms; Female; Hodgkin Disease; Humans; Hydrazines; Laryngeal Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Methylhydrazines; Neoplasms; Pharyngeal Neoplasms; Radioisotope Teletherapy; Sarcoma; Uterine Cervical Neoplasms | 1964 |
[FIRST EVALUATION OF A METHYLHYDRAZINE IN THE TREATMENT OF MALIGNANT GRANULOMA. PRELIMINARY CLINICAL STUDY].
Topics: Biomedical Research; Hodgkin Disease; Humans; Hydrazines; Methylhydrazines; Neoplasms | 1964 |
A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow; Brain; Drug Therapy; Hodgkin Disease; Hydrazines; Leukopenia; Liver; Lung; Methylhydrazines; Neoplasms; Pathology; Pharmacology; Radiography, Thoracic; Thrombocytopenia; Toxicology; Vinblastine | 1965 |
[METHYLHYDRAZINE IN THE TREATMENT OF SOLID TUMORS].
Topics: Adolescent; Antineoplastic Agents; Fluorouracil; Geriatrics; Humans; Hydrazines; Methylhydrazines; Neoplasms | 1965 |
[METHYL-BENZYL HYDRAZINE: A NEW CYTOSTATIC. ITS SIDE-EFFECTS IN VITRO AND IN VIVO].
Topics: Antineoplastic Agents; Cytostatic Agents; Hydrazines; In Vitro Techniques; Neoplasms; Pharmacology; Toxicology | 1965 |
TUMOUR CHEMOTHERAPY IN CHILDREN.
Topics: Child; Cyclophosphamide; Dactinomycin; Hodgkin Disease; Humans; Hydrazines; Methotrexate; Neoplasm Metastasis; Neoplasms; Nephrectomy; Neuroblastoma; Nitrogen Mustard Compounds; Orbital Neoplasms; Pelvic Neoplasms; Rhabdomyosarcoma; Vinblastine; Vincristine; Wilms Tumor | 1965 |
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.
Topics: Animals; Antineoplastic Agents; Cell Survival; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Cross-Linking Reagents; Cytochrome-B(5) Reductase; DNA; Dose-Response Relationship, Drug; Edetic Acid; Glutathione; Glutathione Transferase; Hydrazines; Hypoxia; Mice; Mice, Inbred BALB C; Models, Chemical; NAD(P)H Dehydrogenase (Quinone); NADPH-Ferrihemoprotein Reductase; Neoplasm Transplantation; Neoplasms; Nitrogen; Oxygen; Sulfhydryl Compounds; Sulfonamides; Time Factors; Treatment Outcome; Xanthine Oxidase; Zinc | 2005 |
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Blotting, Western; Cell Line; Cell Line, Tumor; Disease Progression; DNA Methylation; DNA, Complementary; Dose-Response Relationship, Drug; Gene Silencing; Glycerol; Guanine; Hematopoietic Stem Cells; Hydrazines; Inhibitory Concentration 50; Mice; Models, Chemical; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Prodrugs; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sulfonamides; Transfection; Tumor Suppressor Protein p53 | 2005 |
Estimated effects of hydrazine exposure on cancer incidence and mortality in aerospace workers.
Topics: Aged; Aviation; Female; Humans; Hydrazines; Incidence; Los Angeles; Male; Middle Aged; Neoplasms; Occupational Diseases; Occupational Exposure; Proportional Hazards Models | 2006 |
Mortality among Rocketdyne workers who tested rocket engines, 1948-1999.
Topics: Adult; Aviation; California; Cohort Studies; Engineering; Female; Humans; Hydrazines; Industry; Male; Middle Aged; Neoplasms; Occupational Diseases; Occupational Exposure; Retrospective Studies; Solvents; Trichloroethylene | 2006 |
Molecule of the month. Elesclomol and obatoclax mesylate.
Topics: Antineoplastic Agents; Controlled Clinical Trials as Topic; Humans; Hydrazines; Indoles; Melanoma; Neoplasm Metastasis; Neoplasms; Pyrroles | 2008 |
The diagnostic value of circulating trophoblast-specific beta 1-glycoprotein (TSG) in cancer patients.
Topics: Female; Humans; Hydrazines; Male; Neoplasms; Podophyllin; Podophyllotoxin; Pregnancy; Trophoblastic Neoplasms; Uterine Neoplasms | 1980 |
Percutaneous absorption and chemical carcinogenesis.
Topics: Acrylonitrile; Arsenic; Beryllium; Carcinogens; Chloroprene; Chromium; Hair Dyes; Humans; Hydrazines; Neoplasms; Nickel; Nitrosamines; Plastics; Skin Absorption; Styrenes | 1983 |
Occupational exposure to hydrazine and subsequent risk of cancer.
Topics: Chemical Industry; England; Follow-Up Studies; Humans; Hydrazines; Lung Neoplasms; Male; Neoplasms; Occupational Diseases; Risk; Time Factors | 1984 |
Effect of total parenteral nutrition on tumor-host responses in rats.
Topics: Animals; Autoradiography; Body Weight; Cachexia; Gluconeogenesis; Hydrazines; Liver Neoplasms, Experimental; Neoplasms; Parenteral Nutrition; Parenteral Nutrition, Total; Rats; Rats, Inbred BUF; Tryptophan | 1981 |
[Application of the microbial mutation test in occupational health and its future problems (author's transl)].
Topics: Amines; Animals; Carcinogens; Cricetinae; Dogs; Humans; Hydrazines; Mice; Mutagenicity Tests; Mutagens; Neoplasms; Nitro Compounds; Occupational Diseases; Occupational Medicine; Rats | 1981 |
Actual new cancer-causing hydrazines, hydrazides, and hydrazones.
Topics: Animals; Cricetinae; Hydrazines; Hydrazones; Mice; Neoplasms; Rats | 1980 |
Occupational exposure to hydrazine and subsequent risk of cancer.
Topics: Cause of Death; Cohort Studies; Humans; Hydrazines; Male; Neoplasms; Occupational Diseases; Risk Factors; Time Factors | 1995 |
Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again.
Topics: Antineoplastic Agents; Ascorbic Acid; Humans; Hydrazines; Male; Neoplasms; Smoking | 1994 |
Hypoxic mammalian cell radiosensitization by nitric oxide.
Topics: Animals; Cell Hypoxia; Cell Line; Cell Survival; Cricetinae; Cricetulus; Diethylamines; Hydrazines; Molsidomine; Neoplasms; Nitric Oxide; Nitrogen Oxides; Radiation-Sensitizing Agents | 1993 |
[Drug therapy of cancer cachexia].
Topics: Antineoplastic Agents; Cachexia; Glucocorticoids; Histamine Antagonists; Humans; Hydrazines; Neoplasms; Progestins | 1994 |
Hydrazine sulfate ad is "offensive".
Topics: Advertising; Cachexia; Humans; Hydrazines; National Institutes of Health (U.S.); Neoplasms; United States | 1993 |
Re: Biology of cachexia.
Topics: Antineoplastic Agents; Cachexia; Disease Progression; Humans; Hydrazines; Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 1998 |
Molecular handles open the door to novel biomaterials and cancer therapies.
Topics: Biocompatible Materials; Cell Membrane; HeLa Cells; Humans; Hydrazines; Jurkat Cells; Ketones; Mannosides; N-Acetylneuraminic Acid; Neoplasms; Oligosaccharides | 1998 |
More about: biology of cachexia.
Topics: Anti-Anxiety Agents; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Hydrazines; Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 1998 |
Unconventional therapies for cancer: a refuge from the rules of evidence?
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Attitude to Health; Canada; Clinical Trials as Topic; Complementary Therapies; Cooperative Behavior; Government Agencies; Humans; Hydrazines; Neoplasms; Voluntary Health Agencies | 1998 |
Continuing: Biology of cachexia.
Topics: Antineoplastic Agents; Cachexia; Glucose; Humans; Hydrazines; Neoplasms | 1999 |
Continuing: Biology of cachexia.
Topics: Antineoplastic Agents; Cachexia; Drug Interactions; Humans; Hydrazines; Monoamine Oxidase Inhibitors; Neoplasms; Research Design; Retrospective Studies | 1999 |
Unconventional therapies and cancer.
Topics: Antineoplastic Agents; Complementary Therapies; Humans; Hydrazines; Neoplasms; Randomized Controlled Trials as Topic; Research Design | 1999 |
Chemical exposures of rocket-engine test-stand personnel and cancer mortality in a cohort of aerospace workers.
Topics: Carcinogens; Cohort Studies; Humans; Hydrazines; Logistic Models; Lung Neoplasms; Male; Neoplasms; Occupational Diseases; Occupational Exposure; Retrospective Studies; Risk Assessment | 1999 |
Nitrogen intake and tumorigenesis in rats injected with 1,2-dimethylhydrazine.
Topics: Adenocarcinoma; Ammonia; Animals; Blood Urea Nitrogen; Caseins; Cecum; Cholesterol; Colon; Colonic Neoplasms; Dietary Proteins; Dimethylhydrazines; Ear Neoplasms; Female; Hydrazines; Hydrogen-Ion Concentration; Intestinal Neoplasms; Intestine, Small; Neoplasms; Nitrogen; Papilloma; Rats; Urea; Urease | 1976 |
Enhancement of human guanylate cyclase activity by chemical carcinogens.
Topics: Enzyme Activation; Guanylate Cyclase; Humans; Hydrazines; Methylnitrosourea; Neoplasms; Nitrosourea Compounds; Solubility; Streptozocin | 1977 |
[Carcinogenic properties of hydrazines].
Topics: Animals; Carcinogens; Cricetinae; Humans; Hydrazines; Isoniazid; Neoplasms; Rats | 1977 |
[Acute poisoning by Gyromitra esculenta (author's transl)].
Topics: Chemical Phenomena; Chemistry; Female; Humans; Hydrazines; Male; Mushroom Poisoning; Mycotoxins; Neoplasms | 1978 |
Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients.
Topics: Drug Evaluation; Gluconeogenesis; Humans; Hydrazines; Neoplasms; Paresthesia; Remission, Spontaneous | 1975 |
Supportive care drug studies: some promising, some not.
Topics: Amifostine; Antineoplastic Agents; Cachexia; Clodronic Acid; Fractures, Spontaneous; Humans; Hydrazines; Neoplasms | 1992 |
National Cancer Institute's evaluation of unconventional cancer treatments.
Topics: Clinical Protocols; Humans; Hydrazines; National Institutes of Health (U.S.); Neoplasms; United States | 1992 |
Hydrazine sulfate may promote caloric intake and increase survival.
Topics: Energy Intake; Humans; Hydrazines; Neoplasms; Survival Rate | 1988 |
Use of exposure registration in the prevention of occupational cancer in Finland.
Topics: Carcinogens; Finland; Humans; Hydrazines; Information Systems; Neoplasms; Occupational Diseases; Occupations; Registries | 1988 |
Hydrazine: epidemiological evidence.
Topics: Humans; Hydrazines; Male; Neoplasms; Occupational Diseases; Time Factors | 1985 |
Pyridine nucleotides in cancer.
Topics: Antineoplastic Agents; Humans; Hydrazines; Neoplasms; Nucleotides | 1965 |
[Nucleic acid synthesis and cytostatic drug effect in pathological lymph node cells].
Topics: Aged; Antineoplastic Agents; Dactinomycin; Depression, Chemical; DNA, Neoplasm; Hodgkin Disease; Humans; Hydrazines; Hyperplasia; Leukemia; Lymph Nodes; Lymphadenitis; Lymphatic Diseases; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms; Nitrogen Mustard Compounds; Nucleosides; Prednisolone; RNA, Neoplasm; Thymidine; Tritium; Vinblastine | 1966 |
[Chemotherapy of solid tumors. Epitheliomas and sarcomas of non-hematopoietic organs].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Drug Synergism; Humans; Hydrazines; Neoplasms; Plant Extracts; RNA, Neoplasm; Sarcoma | 1971 |
Morphological and biochemical effects of 1,2-dimethylhydrazine and 1-methylhydrazine in rats and mice.
Topics: Animals; Colonic Neoplasms; Dimethylhydrazines; Endoplasmic Reticulum; Hydrazines; Kidney Neoplasms; Lethal Dose 50; Leucine; Liver; Male; Mice; Mitochondria; Monomethylhydrazine; Neoplasms; Neoplasms, Experimental; Rats; Ribosomes | 1974 |
Cancer cachexia and gluconeogenesis.
Topics: Amino Acids; Animals; Body Weight; Cachexia; Energy Metabolism; Gluconeogenesis; Glucose; Glycolysis; Humans; Hydrazines; Kidney Cortex; Lactates; Liver; Neoplasms; Neoplasms, Experimental; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Tryptophan | 1974 |
[Use of cytostatic drugs in therapy and research].
Topics: Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; DNA Replication; Drug Resistance; Ethylamines; Hormones; Humans; Hydrazines; Immunosuppression Therapy; Neoplasms; Nitrogen Mustard Compounds; Transplantation Immunology | 1973 |
The administration of maleic hydrazide and its diethanolamine salt to rats.
Topics: Animals; Ethanolamines; Female; Fibrosarcoma; Hydrazines; Injections, Subcutaneous; Liver Neoplasms; Male; Maleates; Mammary Neoplasms, Experimental; Neoplasms; Pneumonia; Rats; Time Factors | 1973 |
Species dependent toxicity of six substituted hydrazines.
Topics: Allyl Compounds; Animals; Benzoates; Benzyl Compounds; Cricetinae; Dose-Response Relationship, Drug; Hydralazine; Hydrazines; Mice; Neoplasms; Species Specificity | 1974 |
[Efficacy of autologous preserved marrow on patients undergoing myelodepressive therapeutic treatment].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Depression, Chemical; Female; Freezing; Hematopoiesis; Humans; Hydrazines; Injections, Intravenous; Male; Methods; Middle Aged; Neoplasms; Tissue Preservation; Transplantation, Autologous | 1970 |
Combination chemotherapy in malignant disease.
Topics: Administration, Oral; Blood Cell Count; Breast Neoplasms; Bronchial Neoplasms; Child, Preschool; Female; Hodgkin Disease; Humans; Hydrazines; Injections, Intravenous; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Multiple Myeloma; Neoplasms; Prednisolone; Radiography; Remission, Spontaneous; Sarcoma, Ewing; Vinblastine | 1971 |
Possibilities of hazard from nitrosamines in industry.
Topics: Alkylation; Animals; Carcinogens; Environmental Exposure; Esophageal Neoplasms; Female; Humans; Hydrazines; Liver Neoplasms; Neoplasms; Nitrosamines; Occupational Diseases; Occupational Medicine; Pregnancy; Skin Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 1972 |
An outline of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Asparaginase; Breast Neoplasms; Cells, Cultured; Colonic Neoplasms; Cricetinae; DNA, Neoplasm; Humans; Hydrazines; Hydroxyurea; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Mitomycins; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Rats; Ribonucleotides; Ribosomes; RNA, Neoplasm; Transplantation, Heterologous | 1971 |
[Studies on the understanding of problems of radiologic cytostatic combination treatment. 6. Further syncytostatic studies with 5-fluorouracil, natulan and proresid].
Topics: Amides; Animals; Antineoplastic Agents; Cyclophosphamide; Ear, External; Female; Fluorouracil; Granulation Tissue; Hydrazines; Mice; Neoplasms; Plants, Medicinal; Plants, Toxic; Podophyllin; Podophyllum; Radiation Effects; Radiation Injuries, Experimental; Radiotherapy Dosage; Statistics as Topic; Tail; Wound Healing | 1969 |
1-acetyl-2-picolinoylhydrazine (NSC-68626) in the treatment of advanced cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Female; Humans; Hydrazines; Injections, Intravenous; Male; Neoplasms; Picolines | 1969 |
Procarbazine hydrochloride in childhood cancer.
Topics: Adolescent; Adult; Antimetabolites; Child; Child, Preschool; Female; Hodgkin Disease; Humans; Hydrazines; Infant; Leukemia; Lymphoma, Non-Hodgkin; Male; Neoplasms | 1969 |
[Clinical studies of the method of application of antineoplastic agents].
Topics: Antineoplastic Agents; Blood Cell Count; Bone Marrow Examination; Cyclophosphamide; Fluorouracil; Humans; Hydrazines; Injections; Mitomycins; Neoplasms; Phytotherapy; Plants, Medicinal; Plants, Toxic; Podophyllum | 1970 |
[Results of radiologic and cytostatic combination therapy in malignant diseases].
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Hodgkin Disease; Humans; Hydrazines; Lung Neoplasms; Male; Neoplasms | 1967 |
[Clinical observations on the short-term effects of a synthetic antiblastic agent, a derivative of methylhydrazine, with or without radiotherapy].
Topics: Antineoplastic Agents; Humans; Hydrazines; Neoplasms | 1967 |
Epidermal pyridine nucleotides: effect of cancer chemotherapeutic agents on uan epidermal pyridine nucleotides.
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Humans; Hydrazines; Neoplasms; Nucleotides; Pyridines; Skin | 1968 |
[Observations on the use of a recent antineoplastic drug (methylhydrazine) associated with radiotherapy].
Topics: Antineoplastic Agents; Humans; Hydrazines; Neoplasms; Radiation-Sensitizing Agents | 1968 |
Pharmacologic aspects of the chemotherapy of solid tumors.
Topics: Alkylating Agents; Antineoplastic Agents; Dactinomycin; Folic Acid Antagonists; Humans; Hydrazines; Neoplasms; Pyrimidines; Vinblastine; Vincristine | 1968 |
[Experiences with a new cytostatic of the methylhydrazine series (Natulan). With special reference to hematological side-effects].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hemodynamics; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Male; Middle Aged; Neoplasms | 1965 |
The chemotherapy of cancer in children.
Topics: Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Humans; Hydrazines; Mechlorethamine; Methotrexate; Neoplasms; Vinblastine; Vincristine | 1966 |
[Recent acquisitions in cancer chemotherapy].
Topics: Antineoplastic Agents; Humans; Hydrazines; Neoplasms | 1966 |
[The action of Natulan in 94 cases of solid tumors].
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms | 1966 |
[Recent cytostatic therapy in hemoblastosis and malignant tumors].
Topics: Antineoplastic Agents; Hematologic Diseases; Humans; Hydrazines; Neoplasms | 1966 |